Disc Medicine, Inc. $IRON Shares Purchased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA raised its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 10,968.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 394,374 shares of the company’s stock after acquiring an additional 390,811 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Disc Medicine were worth $31,317,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vestal Point Capital LP boosted its stake in shares of Disc Medicine by 257.1% during the third quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock valued at $33,040,000 after acquiring an additional 360,000 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Disc Medicine by 3,329.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock valued at $28,416,000 after purchasing an additional 347,403 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Disc Medicine in the 3rd quarter valued at about $22,342,000. Vanguard Group Inc. boosted its stake in shares of Disc Medicine by 22.1% during the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after purchasing an additional 319,621 shares during the last quarter. Finally, First Light Asset Management LLC acquired a new stake in shares of Disc Medicine during the 3rd quarter worth about $15,277,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Jean M. Franchi sold 7,081 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $65.47, for a total transaction of $463,593.07. Following the completion of the sale, the chief financial officer directly owned 71,343 shares of the company’s stock, valued at $4,670,826.21. The trade was a 9.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of Disc Medicine stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $203,100.66. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at $3,414,806.64. The trade was a 5.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 59,410 shares of company stock worth $3,840,013 over the last 90 days. Company insiders own 3.64% of the company’s stock.

Disc Medicine Trading Down 1.9%

Shares of IRON stock opened at $65.97 on Thursday. The firm has a market cap of $2.52 billion, a P/E ratio of -11.01 and a beta of 0.91. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94. The firm’s 50-day simple moving average is $64.74 and its 200-day simple moving average is $76.21.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The company had revenue of ($19.88) million during the quarter, compared to analysts’ expectations of $0.15 million. As a group, equities analysts forecast that Disc Medicine, Inc. will post -6.68 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IRON. Raymond James Financial reissued a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. BMO Capital Markets cut their price target on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Stifel Nicolaus decreased their price objective on Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Disc Medicine has a consensus rating of “Moderate Buy” and a consensus target price of $104.80.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.